Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07230860 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study of Dermatitis, Atopic, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT07230860: Recruiting Phase 2 study of Dermatitis, Atopic, sponsored by Janssen Research & Development.
NCT07230860 is a Phase 2 study of Dermatitis, Atopic that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 180 participants, below the 391-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07230860, a Phase 2 study of Dermatitis, Atopic, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).
Primary Outcome
EASI-75 response is defined as at least 75 percent (%) improvement from baseline in EASI total score. EASI is a validated measure used to assess the severity and extent of AD with scores ranging from 0 to 72. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) will each be assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvemen
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-95597528
Study Locations (20)
Other
- China Japan Friendship Hospital - Beijing
- Hosp. of Chengde Medical University - Chengde
- Sanmenxia Central Hospital - Sanmenxia
- Wuxi People s Hospital - Wuxi
- Miyata Dermatology Clinic - Matsudo
- Kume Clinic - Nishiku
Ontario
- CCA Medical Research Corporation - Ajax
- SimcoDerm Medical and Surgical Dermatology Centre - Barrie
- DermEdge Research - Mississauga
- XLR8 Medical Research - Windsor
California
- First OC Dermatology - Fountain Valley
- Southern California Dermatology - Santa Ana
Texas
- Center for Clinical Studies - Houston
- Progressive Clinical Research - San Antonio
Florida
- Driven Research LLC - Coral Gables
Illinois
- Arlington Dermatology - Rolling Meadows
Indiana
- Dawes Fretzin Clinical Research Group - Indianapolis
North Dakota
- Red River Research Partners LLC - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2028-02-10 |
| Phase | Phase 2 |
What NCT07230860 shows while recruiting
NCT07230860 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 391-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07230860 names 20 study sites across 10 states, led by Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT07230860 about?
NCT07230860 is a clinical study titled "A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis". The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT07230860?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2026-01-20. Estimated completion is 2028-02-10.
What conditions does trial NCT07230860 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT07230860?
The interventions under investigation include: Placebo (DRUG), JNJ-95597528 (DRUG).
Who is sponsoring clinical trial NCT07230860?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07230860 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07230860's enrollment target sits among peer trials
180 18th of 29 higher than 12 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
COMPLETED · Phase 2
-
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI